Evolution Advisers Inc. Buys New Holdings in Stryker Co. (NYSE:SYK)

Evolution Advisers Inc. bought a new stake in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 300 shares of the medical technology company’s stock, valued at approximately $89,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farmers & Merchants Trust Co of Chambersburg PA increased its position in shares of Stryker by 203.3% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 61 shares during the last quarter. HBC Financial Services PLLC purchased a new stake in shares of Stryker in the 4th quarter worth $37,000. Bourgeon Capital Management LLC purchased a new stake in shares of Stryker in the 4th quarter worth $37,000. Venturi Wealth Management LLC lifted its holdings in shares of Stryker by 97.1% in the 4th quarter. Venturi Wealth Management LLC now owns 136 shares of the medical technology company’s stock worth $41,000 after buying an additional 67 shares during the period. Finally, Armstrong Advisory Group Inc. lifted its holdings in shares of Stryker by 40.0% in the 4th quarter. Armstrong Advisory Group Inc. now owns 140 shares of the medical technology company’s stock worth $42,000 after buying an additional 40 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. Insiders have sold a total of 212,109 shares of company stock valued at $72,845,768 over the last ninety days. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock traded up $0.24 during mid-day trading on Thursday, reaching $337.09. The stock had a trading volume of 1,615,335 shares, compared to its average volume of 1,286,429. The business’s fifty day moving average is $349.16 and its 200-day moving average is $314.40. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The firm has a market cap of $128.25 billion, a price-to-earnings ratio of 40.86, a PEG ratio of 2.70 and a beta of 0.89. Stryker Co. has a 1-year low of $249.98 and a 1-year high of $361.41.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. Stryker’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period last year, the company earned $3.00 earnings per share. On average, research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is 38.79%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a report on Wednesday, January 31st. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Evercore ISI upped their price objective on Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Roth Mkm upped their price objective on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Citigroup upped their price objective on Stryker from $362.00 to $406.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $340.67.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.